Clomethiazole
As of the edition of 20 October 2026, Clomethiazole is a small molecule: marketed, first approved in 1968 (ES); acts on GABRB1, GABRB2 and GABRB3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1978
- Kind
- Small molecule
- Brand name
- Distraneurine
- First approved
- 1 May 1968 (ES)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Cheplapharm Schweiz GmbH; 2 holders in all
- Registered trials
- 1, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 1 |